2-(N-Cbz)-3-(N-Boc)-2,3-二氨基丙酸 | 16947-84-5

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - BOC-氨基酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(N-Cbz)-3-(N-Boc)-2,3-二氨基丙酸
• 中文别名: CBZ-3-BOC-L-2,3-二氨基丙酸；(2S)-3-(叔丁氧羰基氨基)-2-(苄氧羰基氨基)丙酸；N-苄氧羰基-N'-叔丁氧羰基-L-2,3-二氨基丙酸；L-N-CBZ-3-N-BOC-氨基-丙氨酸；(S)-2-(CBZ-氨基)-3-(BOC-氨基)丙酸；(S)-2-(N-CBZ)-3-(N-BOC)-2,3-二氨基丙酸；CBZ-L-(+)-3-N-BOC-2,3-二氨基丙酸；(S)-2-(Cbz-氨基)-3-(Boc-氨基)丙酸；Cbz-3-Boc-L-2,3-二氨基丙酸
• 英文名称: N-[(benzyloxy)carbonyl]-3-[(tert-butoxycarbonyl)amino]-L-alanine
• 英文别名: (S)-2-(((benzyloxy)carbonyl)amino)-3-((tert-butoxycarbonyl)amino)propanoic acid；(S)-2-(((benzyloxy)carbonyl)amino)-3-((t-butoxycarbonyl)amino)propanoic acid；Cbz-L-Dap(Boc)-OH；(S)-3-[(tert-butyloxycarbonyl)-amino]-2-[(benzyloxycarbonyl)-amino]-propanoic acid；(2S)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-2-(phenylmethoxycarbonylamino)propanoic acid
• CAS: 16947-84-5
• 化学式: C₁₆H₂₂N₂O₆
• 分子量: 338.36
• InChiKey: WJKGPJRAGHSOLM-LBPRGKRZSA-N

物化性质

• 沸点：
  548.7±50.0 °C(Predicted)
• 密度：
  1.235±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  114
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• WGK Germany：
  3
• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存储温度应保持在0°C。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Z-Dap(Boc)-OH
CAS-No. : 16947-84-5
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No 1272/2008
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
Caution - substance not yet tested completely.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
: Nα-Z-Nβ-Boc-L-2,3-diaminopropionic acid
Synonyms
Z-3-(Boc-amino)-L-alanine
Formula : C16H22N2O6
Molecular Weight : 338,36 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: powder
Colour: white
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  2-(N-Cbz)-3-(N-Boc)-2,3-二氨基丙酸 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 乙醚 为溶剂， 反应 24.0h， 生成 L-3-N-Boc-2,3-二氨基丙酸甲酯
  参考文献：
  名称：

  细胞生长抑制性环四肽衣原体的类似物。环（Gly-L-Phe-D-Pro-L-Dap）的Nβ-（N-马来酰甘氨酰）和Nβ-（叔丁氧基羰基）衍生物的合成。

  摘要：

  描述了细胞生长抑制性环四肽衣原蛋白的类似物的合成。环（Gly-L-Phe-D-Pro-Nβ-Boc-L-Dap）（4）由Nβ-（叔丁氧羰基）-L-二氨基丙酸甲酯（Dap）和Cbz-Gly-使用DCC / HOBt作为偶联剂的L-Phe-D-Pro。将甲酯皂化为酸，通过与三氯苯酚和DCC反应将其转化为2,4,5-三氯苯基（Tcp）酯。通过氢解除去N-（苄氧羰基）基团，并且使胺活性酯在95℃下在吡啶中环化。分离出Boc保护的环状四肽4，产率为14％。将环四肽4转化为环[[Gly-L-Phe-D-Pro-Nβ-（N-马来酰甘氨酰基）-L-Dap]]（5），以测试衣原蛋白受体上可能存在的巯基。去除叔丁氧羰基，然后与N-马来酰甘氨酸和DCC / HOBt在二氯甲烷中反应，以68％的产率得到环状四肽5。马来酰基环状四肽5不会抑制[3H]胸腺嘧啶核苷掺入小牛胸腺淋巴细胞中，其浓度比衣原霉素（6 nM）的IC50高1000倍。

  DOI：

  10.1021/jm00137a017
• 作为产物：
  描述：

  (S)-2-N-Cbz-3-N-Boc-丙酸甲酯 在 lithium hydroxide 、 水 、 柠檬酸 作用下， 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 反应 1.5h， 生成 2-(N-Cbz)-3-(N-Boc)-2,3-二氨基丙酸
  参考文献：
  名称：

  EP1577302

  摘要：

  公开号：

文献信息

• Antibacterial amide macrocycles VII
  申请人：Endermann Rainer

  公开号：US20080306040A1

  公开（公告）日：2008-12-11

  The invention relates to antibacterial amide macrocycles and methods for their preparation, their use for the treatment and/or prophylaxis of diseases as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, especially bacterial infections.

  这项发明涉及抗菌酰胺大环化合物及其制备方法，其用于治疗和/或预防疾病以及用于生产治疗和/或预防疾病的药物，特别是细菌感染的药物。
• [EN] CEPHEM COMPOUNDS<br/>[FR] CEPHEMES
  申请人：FUJISAWA PHARMACEUTICAL CO

  公开号：WO2005027909A1

  公开（公告）日：2005-03-31

  The present invention relates to a compound of the formula [I]: wherein R1 is lower alkyl or hydroxy (lower) alkyl, and R2 is hydrogen or amino protecting group, or R1 and R2 are bonded together and form lower alkylene ; R3 is -A-R6 wherein A is bond, -NHCO-(CH2CO)n-, lower alkylene, -NH-CO-CO- or the like, and R6 is (a) ou (b) wherein R7, R8, R9 and R10 are independently amino, guanidino, amidino or the like ; R4 is carboxy or protected carboxy; and R5 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.

  本发明涉及一种公式的化合物[I]：其中R1是低级烷基或羟基（低级）烷基，R2是氢或氨基保护基团，或者R1和R2连接并形成低级亚烷基；R3是-A-R6，其中A是键，-NHCO-(CH2CO)n-，低级亚烷基，-NH-CO-CO-或类似物质，R6是(a)或(b)其中R7，R8，R9和R10是独立的氨基，胍基，脒基或类似物质；R4是羧基或受保护的羧基；R5是氨基或受保护的氨基，或药用可接受的盐，一种制备公式化合物[I]的方法，以及一种包括与药用可接受载体混合的公式化合物[I]的药物组合物。
• Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug
  申请人：Jenkins Thomas E.

  公开号：US20120178773A1

  公开（公告）日：2012-07-12

  The embodiments provide Compound KC-7, N-1-[(S)-2-(oxycodone-6-enol-carbonyl-methyl-amino)-2-carbonyl-sarcosine-ethyl amine]-arginine-glycine-acetate, or acceptable salts, solvates, and hydrates thereof. The present disclosure also provides compositions, and their methods of use, where the \compositions comprise a prodrug, Compound KC-7, that provides controlled release of oxycodone. Such compositions can optionally provide a trypsin inhibitor that interacts with the enzyme that mediates the controlled release of oxycodone from the prodrug so as to attenuate enzymatic cleavage of the prodrug.

  提供了一种名为KC-7的化合物，N-1-[(S)-2-(氧可酮-6-烯醇-羰基-甲基-氨基)-2-羰基-肌氨酸-乙胺]-精氨酸-甘氨酸-乙酸盐，或其可接受的盐、溶剂化物和水合物。本公开还提供了包含前药的组合物及其使用方法，其中组合物包含前药KC-7，该前药能够控制释放氧可酮。这样的组合物可以选择性地提供一种胰蛋白酶抑制剂，该抑制剂与介导前药控制释放氧可酮的酶相互作用，以减弱前药的酶切。
• Synthesis of actinomycin and analogs. 12. Synthesis and some properties and antitumor effects of the actinomycin lactam analog, [di-(1'-L-.alpha.,.beta.-diaminopropionic acid)]actinomycin D
  作者：Stanley Moore、Ravindra P. Patel、Eric Atherton、Michio Kondo、Johannes Meienhofer、Lea Blau、Robert Bittman、Randall K. Johnson

  DOI：10.1021/jm00228a006

  日期：1976.6

  -N-methylvalyl)-L-alpha,beta-diaminopropionyl-D-valyl-L-proline p-nitrophenyl ester was prepared by conventional methods of peptide synthesis in solution. Selective cleavage of the Nbeta-tert-butyloxycarbonyl group and lactam formation afforded the desired cyclic pentapeptide derivative. The chromophore precursor, Nalpha-(2-nitro-3-benzyloxy-4-methylbenzoyl) substituent, was introduced via its symmetric

  放线菌素D（AMD）的内酰胺类似物已被合成为潜在的抗肿瘤化学治疗剂。两个L-苏氨酸残基均被L-α，β-二氨基丙酸替代。从Nalpha-苄氧基羰基-Nbeta-叔丁氧基羰基-L-alpha，β-二氨基丙酸甲酯盐酸盐开始，线性中间体Nalpha-苄氧基羰基-Nbeta-（叔丁基氧基羰基糖基-LN-甲基戊基）-L-α，β-二氨基丙酰基-用溶液中肽合成的常规方法制备D-戊基-L-脯氨酸对硝基苯酯。Nβ-叔丁氧基羰基的选择性裂解和内酰胺的形成提供了所需的环状五肽衍生物。经由其对称酸酐引入生色团前体Nalpha-（2-硝基-3-苄氧基-4-甲基苯甲酰基）取代基。催化还原，然后形成铁氰化物介导的苯恶嗪酮，可提供内酰胺类似物[二（1'-L-α，β-二氨基丙酸）]放线菌素D（[Dpr1] 2-AMD）。研究了其与天然和合成DNA的结合以及与含内酰胺（[Dbu1] 2-AMD）的类似L-苏-α，β-二氨基丁酸
• Discovery of an Orally Active Series of Isoxazoline Glycoprotein IIb/IIIa Antagonists
  作者：Chu-Biao Xue、John Wityak、Thais M. Sielecki、Donald J. Pinto、Douglas G. Batt、Gary A. Cain、Michael Sworin、Arlene L. Rockwell、John J. Roderick、Shuaige Wang、Michael J. Orwat、William E. Frietze、Lori L. Bostrom、Jie Liu、C. Anne Higley、F. Wayne Rankin、A. Ewa Tobin、George Emmett、George K. Lalka、Jean Y. Sze、Susan V. Di Meo、Shaker A. Mousa、Martin J. Thoolen、Adrienne L. Racanelli、Elizabeth A. Hausner、Thomas M. Reilly、William F. DeGrado、Ruth R. Wexler、Richard E. Olson

  DOI：10.1021/jm960799i

  日期：1997.6.1

  Using isoxazoline XR299 (1a) as a starting point for the design of highly potent, long-duration GPIIb/IIIa antagonists, the effect of placing lipophilic substituents at positions alpha and beta to the carboxylate moiety was evaluated. Of the compounds studied, it was found that the n-butyl carbamate 24u exhibited superior potency and duration of ex vivo antiplatelet effects in dogs. Replacement of

  使用异恶唑啉XR299（1a）作为设计高效，长效GPIIb / IIIa拮抗剂的起点，评估了将亲脂性取代基置于羧酸酯部分的α和β处的效果。在所研究的化合物中，发现氨基甲酸正丁酯24u在狗中表现出优异的效力和离体抗血小板作用的持续时间。用可替代的碱性基团取代苯并胺丁-4-基部分，消除异恶唑啉立体中心，并改变异恶唑啉环的方向，导致效力和/或作用时间降低。